Is Exelixis a profitable company?
Yes, Exelixis has demonstrated strong commercial performance and financial health, largely driven by its oncology drug Cabometyx [1.1.1]. The company reported significant revenue in 2025 and has provided optimistic growth projections for 2026, supported by the ongoing success of its established cancer treatment franchises and new product launches [1.1.1]. Its strategy combines the reliable revenue from mature assets with continued investment in a next-generation pipeline, positioning the company as a financially robust player in the competitive oncology biopharmaceutical landscape [1.1.1].
Related FAQs
Exelon Corporation, one of the largest utility companies in the United States, holds a generally stable reputation as a reliable provider of electricity to millions of customers.
As of July 2026, Exelixis (EXEL) maintains a "Buy" consensus rating among analysts. The company's stock has demonstrated a strong multi-year performance record, supported by consistent revenue and cash flow from its oncology treatments.
Whether Exelixis (EXEL) is a good stock to buy is a decision that should be based on your personal investment objectives and risk appetite.
Based on the consensus of 14 analysts as of July 24, 2026, Exelixis (EXEL) holds a "Buy" rating. This professional sentiment is driven by the company's historical earnings performance and its role in the biotechnology sector.
Yes, Exelixis is a U.S.-based oncology biopharmaceutical company [1.2.1]. Founded in 1994 and headquartered in Alameda, California, its primary commercial and organizational operations are centered within the United States [1.2.1].